{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:20:09Z","timestamp":1780582809690,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007350","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["233739"],"award-info":[{"award-number":["233739"]}],"id":[{"id":"10.13039\/501100007350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007350","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["Ph.D. Felowship 338858"],"award-info":[{"award-number":["Ph.D. Felowship 338858"]}],"id":[{"id":"10.13039\/501100007350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ovarian cancer is the most aggressive gynecological malignancy. Transcriptional regulators impact the tumor phenotype and, consequently, clinical progression and response to therapy. PHD finger protein 20-like protein 1 (PHF20L1) is a transcriptional regulator with several isoforms, and studies on its role in ovarian cancer are limited. We previously reported that PHF20L1 is expressed as a fucosylated protein in SKOV-3 cells stimulated with ascites from patients with ovarian cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We decided to analyze the expression of PHF20L1 in ovarian cancer tissues, determine whether a correlation exists between PHF20L1 expression and patient clinical data, and analyze whether ascites can modulate the different isoforms of this protein. Ovarian cancer biopsies from 29 different patients were analyzed by immunohistochemistry, and the expression of the isoforms in ovarian cancer cells with or without exposure to the tumor microenvironment, i.e., the ascitic fluid, was determined by western blotting assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Immunohistochemical results suggest that PHF20L1 exhibits increased expression in sections of tumor tissues from patients with ovarian cancer and that higher PHF20L1 expression correlates with shorter progression-free survival and shorter overall survival. Furthermore, western blotting assays determined that protein isoforms are differentially regulated in SKOV-3 cells in response to stimulation with ascites from patients with epithelial ovarian cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The results suggest that PHF20L1 could play a relevant role in ovarian cancer given that higher PHF20L1 protein expression is associated with lower overall patient survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02425-6","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T13:03:00Z","timestamp":1641474180000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["PHD finger protein 20-like protein 1 (PHF20L1) in ovarian cancer: from its overexpression in tissue to its upregulation by the ascites microenvironment"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-9258","authenticated-orcid":false,"given":"Dulce Rosario","family":"Alberto-Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-939X","authenticated-orcid":false,"given":"Ver\u00f3nica Ivonne","family":"Hern\u00e1ndez-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2560-3935","authenticated-orcid":false,"given":"Juan Carlos","family":"Osorio-Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0628-8290","authenticated-orcid":false,"given":"Dolores","family":"Gallardo-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2537-8790","authenticated-orcid":false,"given":"Alfredo","family":"Toledo-Leyva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5085-814X","authenticated-orcid":false,"given":"Patricia","family":"Talam\u00e1s-Rohana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"issue":"11","key":"2425_CR1","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/ijc.30676","volume":"140","author":"S Coburn","year":"2017","unstructured":"Coburn S, Bray F, Sherman M, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140(11):2451\u201360. https:\/\/doi.org\/10.1002\/ijc.30676.","journal-title":"Int J Cancer"},{"issue":"5","key":"2425_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","volume":"30","author":"N Colombo","year":"2019","unstructured":"Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672\u2013705. https:\/\/doi.org\/10.1093\/annonc\/mdz062.","journal-title":"Ann Oncol"},{"issue":"6 Suppl","key":"2425_CR3","doi-asserted-by":"publisher","first-page":"251S","DOI":"10.1016\/s0197-2456(00)00097-0","volume":"21","author":"JK Gohagan","year":"2000","unstructured":"Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 Suppl):251S-72S. https:\/\/doi.org\/10.1016\/s0197-2456(00)00097-0.","journal-title":"Control Clin Trials"},{"issue":"9","key":"2425_CR4","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2174\/15680096113136660102","volume":"13","author":"Y Wang","year":"2013","unstructured":"Wang Y, Shi J, Chai K, Ying X, Zhou BP. The role of snail in EMT and tumorigenesis. Curr Cancer Drug Targets. 2013;13(9):963\u201372.","journal-title":"Curr Cancer Drug Targets"},{"issue":"3","key":"2425_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1158\/0008-5472.CAN-17-1492","volume":"78","author":"F Fang","year":"2018","unstructured":"Fang F, Cardenas H, Huang H, et al. Genomic and epigenomic signatures in ovarian cancer associated with resensitization to platinum drugs. Cancer Res. 2018;78(3):631\u201344.","journal-title":"Cancer Res"},{"issue":"4","key":"2425_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell. 2017;168(4):629\u201343.","journal-title":"Cell"},{"key":"2425_CR7","unstructured":"National Center for Biotechnology Information (NCBI). Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; https:\/\/www.ncbi.nlm.nih.gov\/. Accessed 27 Aug 2020."},{"key":"2425_CR8","unstructured":"Human Protein Atlas. http:\/\/www.proteinatlas.org gene available from v19.3.proteinatlas.org. Accessed 27 Aug 2020."},{"issue":"16","key":"2425_CR9","doi-asserted-by":"publisher","first-page":"eaaz0356","DOI":"10.1126\/sciadv.aaz0356","volume":"6","author":"Y Hou","year":"2020","unstructured":"Hou Y, Liu W, Yi X, et al. PHF20L1 as a H3K27me2 reader coordinates with transcriptional repressors to promote breast tumorigenesis. Sci Adv. 2020;6(16):eaaz0356.","journal-title":"Sci Adv"},{"issue":"2\u20133","key":"2425_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12307-019-00227-z","volume":"12","author":"DR Alberto-Aguilar","year":"2019","unstructured":"Alberto-Aguilar DR, Hern\u00e1ndez-Ram\u00edrez VI, Osorio-Trujillo JC, Gallardo-Rinc\u00f3n D, Toledo-Leyva A, Talam\u00e1s-Rohana P. Ascites from ovarian cancer induces novel fucosylated proteins. Cancer Microenviron. 2019;12(2\u20133):181\u201395.","journal-title":"Cancer Microenviron"},{"issue":"12","key":"2425_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028503","volume":"6","author":"KO Wrzeszczynski","year":"2011","unstructured":"Wrzeszczynski KO, Varadan V, Byrnes J, et al. Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE. 2011;6(12): e28503. https:\/\/doi.org\/10.1371\/journal.pone.0028503.","journal-title":"PLoS ONE"},{"issue":"2","key":"2425_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.molonc.2015.10.013","volume":"10","author":"Y Jiang","year":"2016","unstructured":"Jiang Y, Liu L, Shan W, Yang ZQ. An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer. Mol Oncol. 2016;10(2):292\u2013302.","journal-title":"Mol Oncol"},{"issue":"4","key":"2425_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","volume":"3","author":"IJ Jacobs","year":"2004","unstructured":"Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3(4):355\u201366.","journal-title":"Mol Cell Proteomics"},{"issue":"5\u20136","key":"2425_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1155\/2007\/309382","volume":"23","author":"D Badgwell","year":"2007","unstructured":"Badgwell D, Bast JRC. Early detection of ovarian cancer. Dis Markers. 2007;23(5\u20136):397\u2013410.","journal-title":"Dis Markers"},{"key":"2425_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12953-018-0133-9","volume":"16","author":"A Toledo-Leyva","year":"2018","unstructured":"Toledo-Leyva A, Villegas-Pineda JC, Encarnaci\u00f3n-Guevara S, Gallardo-Rinc\u00f3n D, Talam\u00e1s RP. Effect of ovarian cancer ascites on SKOV-3 cells proteome: new proteins associated with aggressive phenotype in epithelial ovarian cancer. Proteome Science. 2018;16:3. https:\/\/doi.org\/10.1186\/s12953-018-0133-9.","journal-title":"Proteome Science"},{"key":"2425_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13000-014-0221-9","volume":"9","author":"N Fedchenko","year":"2014","unstructured":"Fedchenko N, Reifenrath J. Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue\u2014a review. Diagn Pathol. 2014;9:221.","journal-title":"Diagn Pathol"},{"issue":"2","key":"2425_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.semcdb.2009.09.010","volume":"21","author":"R Bonasio","year":"2010","unstructured":"Bonasio R, Lecona E, Reinberg D. MBT domain proteins in development and disease. Semin Cell Dev Biol. 2010;21(2):221\u201330.","journal-title":"Semin Cell Dev Biol"},{"issue":"2","key":"2425_CR18","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0022-2836(03)00148-7","volume":"327","author":"R Sprangers","year":"2003","unstructured":"Sprangers R, Groves MR, Sinning I, Sattler M. High-resolution X-ray and NMR structures of the SMN Tudor domain: conformational variation in the binding site for symmetrically dimethylated arginine residues. J Mol Biol. 2003;327(2):507\u201320.","journal-title":"J Mol Biol"},{"issue":"4","key":"2425_CR19","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1074\/jbc.C600286200","volume":"282","author":"X Shi","year":"2007","unstructured":"Shi X, Kachirskaia I, Walter KL, et al. Proteome-wide analysis in Saccharomyces cerevisiae identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylated at either lysine 4 or lysine 36. J Biol Chem. 2007;282(4):2450\u20135.","journal-title":"J Biol Chem"},{"issue":"12","key":"2425_CR20","doi-asserted-by":"publisher","first-page":"8277","DOI":"10.1074\/jbc.M113.525279","volume":"289","author":"PO Est\u00e8ve","year":"2014","unstructured":"Est\u00e8ve PO, Terragni J, Deepti K, et al. Methyllysine reader plant homeodomain (PHD) finger protein 20-like 1 (PHF20L1) antagonizes DNA (cytosine-5) methyltransferase 1 (DNMT1) proteasomal degradation. J Biol Chem. 2014;289(12):8277\u201387.","journal-title":"J Biol Chem"},{"key":"2425_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/2045-3701-4-45","volume":"4","author":"E Baxter","year":"2014","unstructured":"Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci. 2014;4:45.","journal-title":"Cell Biosci"},{"issue":"17","key":"2425_CR22","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-04-2509","volume":"11","author":"RT Marquez","year":"2005","unstructured":"Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11(17):6116\u201326.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2425_CR23","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1038\/s41374-018-0106-8","volume":"98","author":"Q Wang","year":"2018","unstructured":"Wang Q, Yu M, Ma Y, et al. PHF20L1 antagonizes SOX2 proteolysis triggered by the MLL1\/WDR5 complexes. Lab Invest. 2018;98(12):1627\u201341.","journal-title":"Lab Invest"},{"issue":"7283","key":"2425_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim R, Mermel CH, Porter D, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899\u2013905.","journal-title":"Nature"},{"issue":"6","key":"2425_CR25","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ceb.2009.09.006","volume":"21","author":"E Laurenti","year":"2009","unstructured":"Laurenti E, Wilson A, Trumpp A. Myc\u2019s other life: stem cells and beyond. Curr Opin Cell Biol. 2009;21(6):844\u201354.","journal-title":"Curr Opin Cell Biol"},{"issue":"2","key":"2425_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2009.07.003","volume":"5","author":"AM Singh","year":"2009","unstructured":"Singh AM, Dalton S. The cell cycle and Myc intersect with mechanisms that regulate pluripotency and reprogramming. Cell Stem Cell. 2009;5(2):141\u20139.","journal-title":"Cell Stem Cell"},{"issue":"5","key":"2425_CR27","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, et al. induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861\u201372.","journal-title":"Cell"},{"issue":"8","key":"2425_CR28","first-page":"804","volume":"108","author":"AD Santin","year":"2001","unstructured":"Santin AD, Bellone S, Ravaggi A, et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG. 2001;108(8):804\u20138.","journal-title":"BJOG"},{"issue":"4","key":"2425_CR29","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3892\/or.2011.1575","volume":"27","author":"ST Wang","year":"2012","unstructured":"Wang ST, Liu JJ, Wang CZ, et al. expression and correlation of Lewis y antigen and TGF-\u03b21 in ovarian epithelial carcinoma. Oncol Rep. 2012;27(4):1065\u201371.","journal-title":"Oncol Rep"},{"issue":"32","key":"2425_CR30","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1038\/s41388-019-0860-0","volume":"38","author":"B Majem","year":"2019","unstructured":"Majem B, Parrilla A, Jim\u00e9nez C, et al. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 2019;38(32):6035\u201350.","journal-title":"Oncogene"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02425-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02425-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T13:17:48Z","timestamp":1641475068000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02425-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2425"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02425-6","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient samples (ascites and tumor tissue) were obtained with the approval of the Research and Ethics Committees (009\/029\/GOI) (CB\/549\/09) of the Instituto Nacional de Cancerolog\u00eda (INCan). Written informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have influenced this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}